{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:46:00Z","timestamp":1794271560923,"version":"4.9.0"},"reference-count":39,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T00:00:00Z","timestamp":1606262400000},"content-version":"unspecified","delay-in-days":24,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>New HIV prevention strategies are urgently required. The discovery of broadly neutralising antibodies (bNAbs) has provided the opportunity to evaluate passive immunisation as a potential prevention strategy and facilitate vaccine development. Since 2014, several bNAbs have been isolated from a clade C-infected South African donor, CAPRISA 256. One particular bNAb, CAP256-VRC26.25, was found to be extremely potent, with good coverage against clade C viruses, the dominant HIV clade in sub-Saharan Africa. Challenge studies in non-human primates demonstrated that this antibody was fully protective even at extremely low doses. This bNAb was subsequently structurally engineered and the clinical variant is now referred to as CAP256V2LS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and analysis<\/jats:title><jats:p>CAPRISA 012B is the second of three trials in the CAPRISA 012 bNAb trial programme. It is a first-in-human, phase I study to assess the safety and pharmacokinetics of CAP256V2LS. The study is divided into four groups. Group 1 is a dose escalation of CAP256V2LS administered intravenously to HIV-negative and HIV-positive women. Group 2 is a dose escalation of CAP256V2LS administered subcutaneously (SC), with and without the dispersing agent recombinant human hyaluronidase (rHuPH20) as single or repeat doses in HIV-negative women. Groups 3 and 4 are randomised placebo controlled to assess two (CAP256V2LS+VRC07-523LS; CAP256V2LS+PGT121) and three (CAP256V2LS+VRC07-523LS+PGT121) bNAb combinations administered SC to HIV-negative women. Safety will be assessed by the frequency of reactogenicity and adverse events related to the study product. Pharmacokinetic disposition of CAP256V2LS alone and in combination with VRC07-523LS and PGT121 will be assessed via dose subgroups and route of administration.<\/jats:p><\/jats:sec><jats:sec><jats:title>Ethics and dissemination<\/jats:title><jats:p>The University of KwaZulu-Natal Biomedical Research Ethics Committee (BREC) and the South African Health Products Regulatory Authority (SAHPRA) have granted regulatory approval (trial reference numbers: BREC00000857\/2019 and SAHPRA 20200123). Trial results will be disseminated through conference presentations, peer-reviewed publications and the clinical trial registry.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration number<\/jats:title><jats:p>PACTR202003767867253; Pre-results.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjopen-2020-042247","type":"journal-article","created":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T06:21:45Z","timestamp":1678861305000},"page":"e042247","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":35,"title":["Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: study protocol for the first-in-human CAPRISA 012B phase I clinical trial"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4530-234X","authenticated-orcid":false,"given":"Sharana","family":"Mahomed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4530-234X","authenticated-orcid":false,"given":"Nigel","family":"Garrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quarraisha A","family":"Karim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nonhlanhla Y","family":"Zuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmund","family":"Capparelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Baxter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanuja","family":"Gengiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derseree","family":"Archary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Samsunder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Doria-Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penny","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan H","family":"Barouch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia E","family":"Fast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Pozzetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Hankins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Carlton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Ledgerwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Mascola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim","family":"Abdool Karim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,11,26]]},"reference":[{"key":"2023101103050785000_10.11.e042247.1","unstructured":"UNAIDS . HIV\/AIDS JUNPo. Geneva: UNAIDS, 2018."},{"key":"2023101103050785000_10.11.e042247.2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(16)30186-2"},{"key":"2023101103050785000_10.11.e042247.3","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.18.2.19408"},{"key":"2023101103050785000_10.11.e042247.4","doi-asserted-by":"publisher","DOI":"10.1056\/nejme1907279"},{"key":"2023101103050785000_10.11.e042247.5","doi-asserted-by":"crossref","first-page":"80","DOI":"10.5539\/ijb.v11n4p80","article-title":"Efficacy, adherence and side effects of PreP for HIV-1 prevention","volume":"11","author":"Fang","year":"2019","journal-title":"Int J Biol"},{"key":"2023101103050785000_10.11.e042247.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1502020"},{"key":"2023101103050785000_10.11.e042247.7","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2174\/1573395514666180605091240","article-title":"Use of monoclonal antibodies to prevent the sexual transmission of human immunodeficiency virus type 1","volume":"15","author":"Anderson","year":"2019","journal-title":"Curr Immunol Rev"},{"key":"2023101103050785000_10.11.e042247.8","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12511"},{"key":"2023101103050785000_10.11.e042247.9","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1974"},{"key":"2023101103050785000_10.11.e042247.10","doi-asserted-by":"publisher","DOI":"10.1038\/nature10373"},{"key":"2023101103050785000_10.11.e042247.11","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1214785109"},{"key":"2023101103050785000_10.11.e042247.12","doi-asserted-by":"publisher","DOI":"10.1038\/nature12744"},{"key":"2023101103050785000_10.11.e042247.13","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-018-0235-7"},{"key":"2023101103050785000_10.11.e042247.14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0001954"},{"key":"2023101103050785000_10.11.e042247.15","doi-asserted-by":"publisher","DOI":"10.1038\/nature13036"},{"key":"2023101103050785000_10.11.e042247.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2018.09.001"},{"key":"2023101103050785000_10.11.e042247.17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005520"},{"key":"2023101103050785000_10.11.e042247.18","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02658-10"},{"key":"2023101103050785000_10.11.e042247.19","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3963"},{"key":"2023101103050785000_10.11.e042247.20","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01791-15"},{"key":"2023101103050785000_10.11.e042247.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.03.052"},{"key":"2023101103050785000_10.11.e042247.22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002493"},{"key":"2023101103050785000_10.11.e042247.23","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aal1321"},{"key":"2023101103050785000_10.11.e042247.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2019.08.014"},{"key":"2023101103050785000_10.11.e042247.25","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1007\/s13361-018-1968-0","article-title":"Investigation of sequence clipping and structural heterogeneity of an HIV broadly neutralizing antibody by a comprehensive LC-MS analysis","volume":"29","author":"Ivleva","year":"2018","journal-title":"J Am Soc Mass Spectrom"},{"key":"2023101103050785000_10.11.e042247.26","unstructured":"Vaccine Research Centre . Investigators brochure CAP256V2LS (VRC-HIVMAB 0102-00-AB), version 10, 2020 [Accessed 12 Feb 2020]."},{"key":"2023101103050785000_10.11.e042247.27","doi-asserted-by":"publisher","DOI":"10.3233\/HAB-2005-143-402"},{"key":"2023101103050785000_10.11.e042247.28","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.25234"},{"key":"2023101103050785000_10.11.e042247.29","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-030283"},{"key":"2023101103050785000_10.11.e042247.30","doi-asserted-by":"crossref","first-page":"e667","DOI":"10.1016\/S2352-3018(19)30181-X","article-title":"Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial","volume":"6","author":"Gaudinski","year":"2019","journal-title":"Lancet HIV"},{"key":"2023101103050785000_10.11.e042247.31","unstructured":"Stephenson K , Julg B , Ansel J , et al . Therapeutic activity of PGT121 monoclonal antibody in HIV-infected adults. Conference on retroviruses and opportunistic infections; Seattle, Washington 2019."},{"key":"2023101103050785000_10.11.e042247.32","article-title":"Clinical trials of broadly neutralizing monoclonal antibodies for HIV prevention: a review","author":"Mahomed","year":"2020","journal-title":"J Infect Dis"},{"key":"2023101103050785000_10.11.e042247.33","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1080\/10717544.2018.1551442","article-title":"ENHANZE\u00ae drug delivery technology: a novel approach to subcutaneous administration using recombinant human hyaluronidase PH20","volume":"26","author":"Locke","year":"2019","journal-title":"Drug Deliv"},{"key":"2023101103050785000_10.11.e042247.34","doi-asserted-by":"crossref","first-page":"537","DOI":"10.5414\/CP201847","article-title":"Pharmacokinetics and pharmacodynamics of single subcutaneous doses of tocilizumab administered with or without rHuPH20","volume":"51","author":"Morcos","year":"2013","journal-title":"Int J Clin Pharmacol Ther"},{"key":"2023101103050785000_10.11.e042247.35","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2011.0115"},{"key":"2023101103050785000_10.11.e042247.36","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.371"},{"key":"2023101103050785000_10.11.e042247.37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0131906","article-title":"Randomized cross-sectional study to compare HIV-1 specific antibody and cytokine concentrations in female genital secretions obtained by menstrual cup and cervicovaginal lavage","volume":"10","author":"Archary","year":"2015","journal-title":"PLoS One"},{"key":"2023101103050785000_10.11.e042247.38","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S2055-6640(20)30009-1","article-title":"A collaborative, multidisciplinary approach to HIV transmission risk mitigation during analytic treatment interruption","volume":"6","author":"Peluso","year":"2020","journal-title":"J Virus Erad"},{"key":"2023101103050785000_10.11.e042247.39","doi-asserted-by":"crossref","first-page":"e259","DOI":"10.1016\/S2352-3018(19)30052-9","article-title":"Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting","volume":"6","author":"Julg","year":"2019","journal-title":"Lancet HIV"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2020-042247","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T10:09:50Z","timestamp":1697018990000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2020-042247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":39,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11,26]]},"published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.1136\/bmjopen-2020-042247"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2020-042247","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11]]}}}